Browse by Research Team

Diabetes Obesity and Metabolism

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender, S. and Schuster, H. and Barter, P. and Watkins, C. and Kallend, D.
Diabetes Obesity and Metabolism 7 : 430-438. 1 January 2005

Diabetologia

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Fagerberg, B. and Edwards, S. and Halmos, T. and Lopatynski, J. and Schuster, H. and Stender, S. and Stoa-Birketvedt, G. and Tonstad, S. and Halldorsdottir, S. and Gause-Nilsson, I.
Diabetologia 48 : 1716-1725. 7 July 2005

Evidence-Based Cardiovascular Medicine

Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.
Fonseca, F.A. and Izar, M.C. and Silva, M.A. and Karapanos, A. and Schuster, H. and Singh, D.
Evidence-Based Cardiovascular Medicine 10 : 96-100. June 2006

Expert Review of Cardiovascular Therapy

The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
Schuster, H.
Expert Review of Cardiovascular Therapy 5 (2): 177-193. March 2007

International Journal of Cardiology

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung, R.C. and Morrell, J.M. and Kallend, D. and Watkins, C. and Schuster, H.
International Journal of Cardiology 100 : 309-316. 1 January 2005

Nature Clinical Practice Cardiovascular Medicine

Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?
Schuster, H.
Nature Clinical Practice Cardiovascular Medicine 3 : 74-75. February 2006